journal
Journals European Journal of Medicinal ...

European Journal of Medicinal Chemistry

https://read.qxmd.com/read/37783102/design-and-synthesis-of-4th-generation-egfr-inhibitors-against-human-triple-del19-t790m-c797s-mutation
#1
JOURNAL ARTICLE
Jiyoung Jeon, Sun Young Jang, Eun Joo Kwak, Sun Hoe Lee, Joo-Yun Byun, Yu-Yon Kim, Young Gil Ahn, Pargat Singh, Kyeongwon Moon, In Su Kim
Epidermal growth factor receptor (EGFR)-targeted therapy is used to treat EGFR mutation-induced non-small cell lung cancer (NSCLC). However, its efficacy does not last beyond a certain period due to the development of primary and secondary resistance. First and second-generation inhibitors (e.g., gefitinib, erlotinib, and afatinib) induce EGFR T790M mutations, while third-generation inhibitors (e.g., osimertinib) induce C797S as a major target resistance mutation. Therefore, the C797S mutation is being actively researched...
September 27, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37778240/targeted-protein-degradation-in-drug-development-recent-advances-and-future-challenges
#2
REVIEW
Jian Song, Mingzheng Hu, Jun Zhou, Songbo Xie, Tianliang Li, Yan Li
Targeted protein degradation (TPD) has emerged as a promising therapeutic approach with potential advantages over traditional occupancy-based inhibitors in terms of dosing, side effects and targeting "undruggable" proteins. Targeted degraders can theoretically bind any nook or cranny of targeted proteins to drive degradation. This offers convenience versus the small-molecule inhibitors that must function in a well-defined pocket. The degradation process depends mainly on two cell self-destruction mechanisms, namely the ubiquitin-proteasome system and the lysosomal degradation pathway...
September 27, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37778239/inhibition-of-son-of-sevenless-homologue-1-sos1-promising-therapeutic-treatment-for-kras-mutant-cancers
#3
REVIEW
Tingkai Chen, Xu Tang, Zhenqi Wang, Feng Feng, Chunlei Xu, Qun Zhao, Yulan Wu, Haopeng Sun, Yao Chen
Kristen rat sarcoma (KRAS) is one of the most common oncogenes in human cancers. As a guanine nucleotide exchange factor, Son of Sevenless Homologue 1 (SOS1) represents a potential therapeutic concept for the treatment of KRAS-mutant cancers because of its activation on KRAS and downstream signaling pathways. In this review, we provide a comprehensive overview of the structure, biological function, and regulation of SOS1. We also focus on the recent advances in SOS1 inhibitors and emphasize their binding modes, structure-activity relationships and pharmacological activities...
September 25, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37776573/strategies-for-developing-retinoic-acid-receptor-alpha-selective-antagonists-as-novel-agents-for-male-contraception
#4
JOURNAL ARTICLE
Md Abdullah Al Noman, Rebecca A D Cuellar, Jillian L Kyzer, Sanny S W Chung, Narsihmulu Cheryala, Trinh A D Holth, Soma Maitra, Tahmina Naqvi, Henry L Wong, Ernst Schönbrunn, Jon E Hawkinson, Debra J Wolgemuth, Gunda I Georg
Reported here are the synthesis and in vitro evaluation of a series of 26 retinoic acid analogs based on dihydronaphthalene and chromene scaffolds using a transactivation assay. Chromene amide analog 21 was the most potent and selective retinoic acid receptor α antagonist identified from this series. In vitro evaluation indicated that 21 has favorable physicochemical properties and a favorable pharmacokinetic PK profile in vivo with significant oral bioavailability, metabolic stability, and testes exposure...
September 25, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37774507/kinetic-modelling-of-the-p-glycoprotein-mediated-efflux-with-a-large-scale-matched-molecular-pair-analysis
#5
JOURNAL ARTICLE
Hongtao Zhao
P-glycoprotein (Pgp) mediated efflux impacts on the drug absorption, distribution, metabolism and excretion, and confers multidrug resistance to cancer cells. Kinetic modelling provides mechanistic insights into the relationship between the substrate-Pgp interactions and efflux, and bridges the gap between the preference of polar compounds as Pgp substrates and the hydrophobic nature of its drug-binding site. Matched molecular pair analysis supports the guidelines of controlling H-bond donors and polar surface area in the efflux mitigation, but also reveals insufficiency of this type of rule-based approach...
September 24, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37783101/design-synthesis-and-biological-evaluation-of-novel-2-4-thiazolidinedione-derivatives-able-to-target-the-human-bag3-protein
#6
JOURNAL ARTICLE
Federica Budassi, Chiara Marchioro, Martina Canton, Annagiulia Favaro, Mattia Sturlese, Chiara Urbinati, Marco Rusnati, Romeo Romagnoli, Giampietro Viola, Elena Mariotto
The Bcl-2-associated athanogene 3 (BAG3) protein plays multiple roles in controlling cellular homeostasis, and it has been reported to be deregulated in many cancers, leading tumor cell apoptosis escape. BAG3 protein is then an emerging target for its oncogenic activities in both leukemia and solid cancers, such as medulloblastoma. In this work a series of forty-four compounds were designed and successfully synthesized by the modification and optimization of a previously reported 2,4-thiazolidinedione derivative 28...
September 22, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37757658/recent-advance-of-clinically-approved-small-molecule-drugs-for-the-treatment-of-myeloid-leukemia
#7
REVIEW
Zhen-Xi Niu, Ya-Tao Wang, Jin-Feng Sun, Peng Nie, Piet Herdewijn
Myeloid leukemia denotes a hematologic malignancy characterized by aberrant proliferation and impaired differentiation of blood progenitor cells within the bone marrow. Despite the availability of several treatment options, the clinical outlook for individuals afflicted with myeloid leukemia continues to be unfavorable, making it a challenging disease to manage. Over the past, substantial endeavors have been dedicated to the identification of novel targets and the advancement of enhanced therapeutic modalities to ameliorate the management of this disease, resulting in the discovery of many clinically approved small-molecule drugs for myeloid leukemia, including histone deacetylase inhibitors, hypomethylating agents, and tyrosine kinase inhibitors...
September 22, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37748386/exploring-novel-anticancer-pyrazole-benzenesulfonamides-featuring-tail-approach-strategy-as-carbonic-anhydrase-inhibitors
#8
JOURNAL ARTICLE
Rehab F Ahmed, Walaa R Mahmoud, Nagwa M Abdelgawad, Marwa A Fouad, Mona F Said
This study aimed to design potent carbonic anhydrase inhibitors (CAIs) based on pyrazole benzenesulfonamide core. Nine series of substituted pyrazole benzenesulfonamide compounds were synthesized with variable groups like sulphamoyl group as in compounds 4a-e, its bioisosteric carboxylic acid as in compounds 5a-e and 8e, ethyl carboxylate ester as in compounds 6a-e and 9a-e, which were designed as potential prodrugs, isothiazole ring as in compound 7, hydrazide derivative 10e, hydroxamic acid derivatives 11a-e and semicarbazide derivatives 12a-c,e...
September 19, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37741183/development-of-a-nir-fluorescent-probe-for-fluorescence-assisted-egfr-tki-applicable-patients-screening-and-drug-resistance-monitoring
#9
JOURNAL ARTICLE
Xinmiao Lu, Muyu Wu, Quanyong Luo
EGFR tyrosine kinase inhibitor exerts significant benefits to non-small cell lung cancer patient, but was also limited by the applicable patient screening and drug resistance. Here we presented with an EGFR-targeted and reactive oxygen species-responsive NIR probe (LX) to achieve both patient screening and drug resistance monitoring for EGFR-tyrosine kinase inhibitor. LX inherited EGFR selectivity and preference from EGFR-tyrosine kinase inhibitor, which only showed specificity to tumor with EGFR mutation. Meanwhile, the near-infrared fluorescence of LX was initially inhibited and could be turned on by intratumoral reactive oxygen species...
September 19, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37776574/evaluation-of-novel-pyrazol-4-yl-pyridine-derivatives-possessing-arylsulfonamide-tethers-as-c-jun-n-terminal-kinase-jnk-inhibitors-in-leukemia-cells
#10
JOURNAL ARTICLE
Karim I Mersal, Mohammed S Abdel-Maksoud, Eslam M H Ali, Usama M Ammar, Seyed-Omar Zaraei, Md Mamunul Haque, Tanuza Das, Noha F Hassan, Eunice EunKyeong Kim, Jun-Seok Lee, HaJeung Park, Kwan Hyi Lee, Mohammed I El-Gamal, Hee-Kwon Kim, Tamer M Ibrahim, Chang-Hyun Oh
A series of 36 pyrazol-4-yl pyridine derivatives (8a-i, 9a-i, 10a-i, and 11a-i) was designed, synthesized, and evaluated for its antiproliferative activity over NCI-60 cancer cell line panel and inhibitory effect against JNK isoforms (JNK1, JNK2, and JNK3). All the synthesized compounds were tested against the NCI-60 cancer cell line panel. Compounds 11b, 11c, 11g, and 11i were selected to determine their GI50s and exerted a superior potency over the reference standard SP600125 against the tested cell lines...
September 15, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37748387/synthesis-and-evaluation-of-aromatic-bdsf-bioisosteres-on-biofilm-formation-and-colistin-sensitivity-in-pathogenic-bacteria
#11
JOURNAL ARTICLE
Andromeda-Celeste Gómez, Conor Horgan, Daniel Yero, Marc Bravo, Xavier Daura, Michelle O'Driscoll, Isidre Gibert, Timothy P O'Sullivan
The diffusible signal factor family (DSF) of molecules play an important role in regulating intercellular communication, or quorum sensing, in several disease-causing bacteria. These messenger molecules, which are comprised of cis-unsaturated fatty acids, are involved in the regulation of biofilm formation, antibiotic tolerance, virulence and the control of bacterial resistance. We have previously demonstrated how olefinic N-acyl sulfonamide bioisosteric analogues of diffusible signal factor can reduce biofilm formation or enhance antibiotic sensitivity in a number of bacterial strains...
September 15, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37776575/tea-break-with-epigallocatechin-gallate-derivatives-powerful-polyphenols-of-great-potential-for-medicine
#12
REVIEW
Paweł Bakun, Dariusz T Mlynarczyk, Tomasz Koczorowski, Magdalena Cerbin-Koczorowska, Ludwika Piwowarczyk, Emil Kolasiński, Maciej Stawny, Joanna Kuźmińska, Anna Jelińska, Tomasz Goslinski
Epigallocatechin gallate (EGCG) is a polyphenol present in green tea (Camellia sinensis), which has revealed anti-cancer effects toward a variety of cancer cells in vitro and protective potential against neurodegenerative diseases such as Alzheimer's and Parkinson's. Unfortunately, EGCG presents disappointing bioavailability after oral administration, primarily due to its chemical instability and poor absorption. Due to these limitations, EGCG is currently not used in medication, but only as a dietary supplement in the form of green tea extract...
September 14, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37729693/synthesis-cytotoxic-activity-evaluation-and-mechanistic-investigation-of-novel-3-7-diarylsubstituted-6-azaindoles
#13
JOURNAL ARTICLE
Nikolaos Lougiakis, Nikolaos Sakalis, Maria Georgiou, Panagiotis Marakos, Nicole Pouli, Alexios-Leandros Skaltsounis, Eleni Mavrogonatou, Harris Pratsinis, Dimitris Kletsas
A number of new disubstituted 6-azaindoles have been designed and synthesized bearing a crucial structural modification in respect to an analogous antiproliferative hit compound. The synthesis was performed using 2-amino-3-nitro-4-picoline, that was suitably modified and converted to 7-chloro-3-iodo-6-azaindole and this central scaffold was used for successive Suzuki-type couplings, to result in the target compounds. The evaluation of the cytotoxic activity was performed against four human cancer cell lines, as well as a normal human fibroblast strain...
September 13, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37722288/targeting-protein-kinases-for-the-treatment-of-alzheimer-s-disease-recent-progress-and-future-perspectives
#14
REVIEW
Zhijia Li, Bo Yin, Shuangqian Zhang, Zhigang Lan, Lan Zhang
Alzheimer's disease (AD) is a serious neurodegenerative disease characterized by memory impairment, mental retardation, impaired motor balance, loss of self-care and even death. Among the complex and diverse pathological changes in AD, protein kinases are deeply involved in abnormal phosphorylation of Tau proteins to form intracellular neuronal fiber tangles, neuronal loss, extracellular β-amyloid (Aβ) deposits to form amyloid plaques, and synaptic disturbances. As a disease of the elderly, the growing geriatric population is directly driving the market demand for AD therapeutics, and protein kinases are potential targets for the future fight against AD...
September 13, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37734258/galantamine-memantine-hybrids-for-alzheimer-s-disease-the-influence-of-linker-rigidity-in-biological-activity-and-pharmacokinetic-properties
#15
JOURNAL ARTICLE
Filippo Basagni, Jose A Ortega, Sine M Bertozzi, Andrea Armirotti, Maria Summa, Rosalia Bertorelli, Manuela Bartolini, Ian R Mellor, Martina Bedeschi, Giovanni Bottegoni, Vittorio Lembo, Anna Minarini, Andrea Cavalli, Michela Rosini
Neurodegenerative processes characterizing Alzheimer's disease (AD) are strictly related to the impairment of cholinergic and glutamatergic neurotransmitter systems which provoke synaptic loss. These experimental evidences still represent the foundation of the actual standard-of-care treatment for AD, albeit palliative, consisting on the coadministration of an acetylcholinesterase inhibitor and the NMDAR antagonist memantine. In looking for more effective treatments, we previously developed a series of galantamine-memantine hybrids where compound 1 (ARN14140) emerged with the best-balanced action toward the targets of interest paired to neuroprotective efficacy in a murine AD model...
September 12, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37722289/design-synthesis-and-anti-respiratory-syncytial-virus-potential-of-novel-3-1-2-3-triazol-1-yl-furoxazine-fused-benzimidazole-derivatives
#16
JOURNAL ARTICLE
Lu Mao, Song Wang, Ying Qu, Haixia Wang, Yifan Zhao, Chuantao Zhu, Zhongmou Zhang, Chengyun Jin, Piet Herdewijn, Feng-Wu Liu, Zhenya Wang
Respiratory syncytial virus (RSV) is a major cause of serious lower respiratory tract infections in infants, children, and older persons. Currently, the only approved anti-viral chemotherapeutic drug for RSV treatment is ribavirin aerosol; however, its significant toxicity has led to restricted clinical use. In a previous study, we developed various benzimidazole derivatives against RSV. In this study, we synthesised 3-azide substituted furoxazine-fused benzimidazole derivatives by sulfonylation and azide substitution of the 3-hydroxyl group of the furoxazine-fused benzimidazole derivatives...
September 12, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37717381/a-dipyridophenazine-ni-ii-dithiolene-complex-as-a-dual-acting-cancer-phototherapy-agent-activatable-within-the-phototherapeutic-window
#17
JOURNAL ARTICLE
Tukki Sarkar, Somarupa Sahoo, Suditi Neekhra, Milan Paul, Swati Biswas, Bathini Nagendra Babu, Rohit Srivastava, Akhtar Hussain
A combination of photodynamic therapy (PDT) and photothermal therapy (PTT) within the phototherapeutic window (600-900 nm) can lead to significantly enhanced therapeutic outcomes, surpassing the efficacy observed with PDT or PTT alone in cancer phototherapy. Herein, we report a novel small-molecule mixed-ligand Ni(II)-dithiolene complex (Ni-TDD) with a dipyridophenazine ligand, demonstrating potent red-light PDT and significant near-infrared (NIR) light mild-temperature PTT activity against cancer cells and 3D multicellular tumour spheroids (MCTSs)...
September 12, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37713805/applications-of-oxetanes-in-drug-discovery-and-medicinal-chemistry
#18
REVIEW
Guang Huang, Devon Hucek, Tomasz Cierpicki, Jolanta Grembecka
The compact and versatile oxetane motifs have gained significant attention in drug discovery and medicinal chemistry campaigns. This review presents an overview of the diverse applications of oxetanes in clinical and preclinical drug candidates targeting various human diseases, including cancer, viral infections, autoimmune disorders, neurodegenerative conditions, metabolic disorders, and others. Special attention is given to biologically active oxetane-containing compounds and their disease-related targets, such as kinases, epigenetic and non-epigenetic enzymes, and receptors...
September 11, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37713804/progress-in-the-development-of-trpv1-small-molecule-antagonists-novel-strategies-for-pain-management
#19
REVIEW
Kun Zhu, Lin Wang, TingTing Liao, Wen Li, Jing Zhou, Yaodong You, Jianyou Shi
Transient receptor potential vanilloid 1 (TRPV1) channels are widely distributed in sensory nerve endings, the central nervous system, and other tissues, functioning as ion channel proteins responsive to thermal pain and chemical stimuli. In recent years, the TRPV1 receptor has garnered significant interest as a potential therapeutic approach for various pain-related disorders, particularly TRPV1 antagonists. The present review offers a comprehensive, systematic exploration of both first- and second-generation TRPV1 antagonists in the context of pain management...
September 9, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37708798/technologies-of-targeting-histone-deacetylase-in-drug-discovery-current-progress-and-emerging-prospects
#20
REVIEW
Jinxiao Ru, Yuxi Wang, Zijia Li, Jiaxing Wang, Changyu Ren, Jifa Zhang
Histone deacetylases (HDACs) catalyze the hydrolysis of acetyl-l-lysine side chains in histones and non-histones, which are key to epigenetic regulation in humans. Targeting HDACs has emerged as a promising strategy for treating various types of cancer, including myeloma and hematologic malignancies. At present, numerous small molecule inhibitors targeting HDACs are actively being investigated in clinical trials. Despite their potential efficacy in cancer treatment, HDAC inhibitors suffer from multi-directional selectivity and preclinical resistance issues...
September 9, 2023: European Journal of Medicinal Chemistry
journal
journal
24926
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.